Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Dense Deposit DiseaseMembranoproliferative Glomerulonephritis
Interventions
DRUG

Eculizumab

Dosage/Frequency: 900 mg IV once a week for 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.

Trial Locations (2)

10032

Columbia University Medical Center, Glomerular Center, New York

Columbia University Medical Center, Nephrology Clinical Research Center, New York

Sponsors
All Listed Sponsors
collaborator

Alexion Pharmaceuticals, Inc.

INDUSTRY

lead

Columbia University

OTHER